Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890368 · ClinicalTrials.gov registry record · Phase 1
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02890368: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT02890368 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02890368, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.
Primary Outcome
Defining the optimal TTI-621 delivery regimen in subjects with advanced percutaneously-accessible cancer
Interventions
- DRUG TTI-621 Monotherapy
- DRUG TTI-621 + PD-1/PD-L1 Inhibitor
- DRUG TTI-621 + pegylated interferon-α2a
- OTHER TTI-621 + T-Vec
- OTHER TTI-621 + radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Why NCT02890368 stopped before completion
NCT02890368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which TTI-621 Monotherapy is the first listed.
NCT02890368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02890368 about?
NCT02890368 is a clinical study titled "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides". This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase an...
What is the current status of trial NCT02890368?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2016-09. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02890368?
The interventions under investigation include: TTI-621 Monotherapy (DRUG), TTI-621 + PD-1/PD-L1 Inhibitor (DRUG), TTI-621 + pegylated interferon-α2a (DRUG), TTI-621 + T-Vec (OTHER), TTI-621 + radiation (OTHER).
Who is sponsoring clinical trial NCT02890368?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02890368's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia